Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 15,868 shares at $85.60 ($1.4M) on 2024-11-18, disclosed to the SEC on 2024-11-19.
Scheduled sale ($1.4M) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $85.60 | 6,111 | $523K | 38.4% |
| 2 | $85.60 | 6,111 | $523K | 38.4% |
| 3 | $86.49 | 1,757 | $152K | 11.2% |
| 4 | $86.49 | 1,757 | $152K | 11.2% |
| 5 | $87.05 | 132 | $11K | 0.8% |
| Total | $85.81 avg | 15,868 |
| $1.4M |
| 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-02-19 | $1.3M | — | Filing → |
| PCVX | SELL | 2025-01-22 | $1.4M | — | Filing → |